We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+32.76%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$5.72B
AUM Growth
+$1.24B
Cap. Flow
+$495M
Cap. Flow %
8.66%
Top 10 Hldgs %
39.54%
Holding
129
New
28
Increased
37
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$84.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$72.9M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$65.7M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$65.1M
5
PCVX icon
Vaxcyte
PCVX
+$58.5M

Top Sells

Rank Stock Value
1
LIAN
LianBio American Depositary Shares
LIAN
+$257M
2
CBAY
Cymabay Therapeutics
CBAY
+$95.1M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$46.3M
4
ACLX
Arcellx
ACLX
+$38.8M
5
ABBV icon
AbbVie
ABBV
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.28%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERE
1
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$456M 7.98%
10,794,876
-170,317
-2% -$7.15M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$331M 5.78%
28,057,456
– –
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.02B
$286M 5%
19,272,991
+7,293,576
+61% +$84.9M
ACLX
4
DELISTED
Arcellx
ACLX
$274M 4.79%
3,933,556
-611,253
-13% -$38.8M
NUVL
5
DELISTED
Nuvalent
NUVL
$209M 3.66%
2,783,454
-134,537
-5% -$10.7M
INBX
6
DELISTED
Inhibrx, Inc. Common Stock
INBX
$149M 2.6%
4,256,104
– –
FUSN
7
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$146M 2.55%
6,825,395
+4,074,000
+148% +$48.7M
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$7.34B
$142M 2.48%
3,268,579
+1,114,469
+52% +$48.8M
APGE icon
9
Apogee Therapeutics
APGE
$10.1B
$137M 2.4%
2,060,395
+232,494
+13% +$10.2M
PCVX icon
10
Vaxcyte
PCVX
$7.65B
$132M 2.31%
1,932,759
+844,273
+78% +$58.5M
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$132M 2.3%
3,074,542
– –
MDT icon
12
Medtronic
MDT
$113B
$125M 2.18%
1,429,563
+452,911
+46% +$38.7M
MDGL icon
13
Madrigal Pharmaceuticals
MDGL
$12.4B
$115M 2.01%
429,953
+278,802
+184% +$65.7M
SWTX
14
DELISTED
SpringWorks Therapeutics
SWTX
$111M 1.95%
2,262,462
+305,216
+16% +$14.1M
NBIX icon
15
Neurocrine Biosciences
NBIX
$18.2B
$111M 1.94%
804,409
+533,615
+197% +$72.9M
SYRE icon
16
Spyre Therapeutics
SYRE
$8.28B
$97M 1.7%
2,556,679
-50,000
-2% -$1.45M
IMVT icon
17
Immunovant
IMVT
$7.78B
$95.7M 1.68%
2,963,212
+635,130
+27% +$23.2M
BHVN icon
18
Biohaven
BHVN
$2.03B
$94.3M 1.65%
1,725,047
– –
SLDB icon
19
Solid Biosciences
SLDB
$789M
$92M 1.61%
6,906,646
+3,410,713
+98% +$31.9M
ATXS
20
DELISTED
Astria Therapeutics
ATXS
$91.2M 1.6%
6,485,420
+2,481,350
+62% +$30.9M
AXSM icon
21
Axsome Therapeutics
AXSM
$11.7B
$88.2M 1.54%
1,105,341
+67,322
+6% +$5.65M
VKTX icon
22
Viking Therapeutics
VKTX
$3.83B
$81.5M 1.43%
+994,098
New +$44.2M
EOLS icon
23
Evolus
EOLS
$395M
$80.6M 1.41%
5,753,798
+1,790,374
+45% +$23.3M
LYRA
24
DELISTED
LYRA THERAPEUTICS INC
LYRA
$79.4M 1.39%
255,151
– –
CRGX
25
DELISTED
CARGO Therapeutics
CRGX
$77M 1.35%
3,448,004
+11,404
+0.3% +$271K
1
2 3 4 5

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Perceptive Advisors held 129 positions worth $5.72B, up 28% from $4.48B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Perceptive Advisors deployed $495M of net new capital in Q1 2024, opening 28 new positions and adding to 37 existing holdings. Its largest new stake was CG Oncology: 1,304,105 shares worth $57.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Arcellx, an estimated $38.8M trimmed.

  • Perceptive Advisors's largest Q1 2024 buy was CG Oncology: 1,304,105 shares worth $57.3M.
  • Perceptive Advisors added most to Iovance Biotherapeutics in Q1 2024, an estimated $84.9M increase.
  • Perceptive Advisors's biggest Q1 2024 reduction was Arcellx, cutting an estimated $38.8M.
  • Perceptive Advisors fully exited LianBio American Depositary Shares in Q1 2024, selling an estimated $257M.
  • Perceptive Advisors's ten largest holdings make up 40% of its $5.72B portfolio in Q1 2024.
  • Perceptive Advisors opened 28 new positions and closed 17 in Q1 2024.
  • Perceptive Advisors's portfolio value rose 28% quarter-over-quarter to $5.72B.

Based on Perceptive Advisors's 13F filing for Q1 2024, filed 15 May 2024.